These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Recent progress in synthetic self-adjuvanting vaccine development. Ariawan D; van Eersel J; Martin AD; Ke YD; Ittner LM Biomater Sci; 2022 Jul; 10(15):4037-4057. PubMed ID: 35708540 [TBL] [Abstract][Full Text] [Related]
7. Chemical Strategies to Boost Cancer Vaccines. Li WH; Li YM Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967 [TBL] [Abstract][Full Text] [Related]
8. Polyethyleneimine-based immunoadjuvants for designing cancer vaccines. Yang X; Wei Y; Zheng L; You J; Li H; Gao L; Gong C; Yi C J Mater Chem B; 2022 Oct; 10(40):8166-8180. PubMed ID: 36217765 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication. Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937 [TBL] [Abstract][Full Text] [Related]
10. Advances in Cancer Vaccine Research. Liu N; Xiao X; Zhang Z; Mao C; Wan M; Shen J ACS Biomater Sci Eng; 2023 Nov; 9(11):5999-6023. PubMed ID: 37921277 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Vaccines for Cancer Immunotherapy. Wang J; Mamuti M; Wang H ACS Biomater Sci Eng; 2020 Nov; 6(11):6036-6052. PubMed ID: 33449675 [TBL] [Abstract][Full Text] [Related]
13. Antigen-specific vaccines for cancer treatment. Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639 [TBL] [Abstract][Full Text] [Related]
14. Tumor cell-based vaccine: an effective strategy for eradication of cancer cells. Sadeghi Najafabadi SA; Bolhassani A; Aghasadeghi MR Immunotherapy; 2022 Jun; 14(8):639-654. PubMed ID: 35481358 [TBL] [Abstract][Full Text] [Related]
15. Genetically modified tumour vaccines--where we are today. Nawrocki S; Mackiewicz A Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588 [TBL] [Abstract][Full Text] [Related]
16. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Tefit JN; Serra V Expert Rev Vaccines; 2011 Aug; 10(8):1207-20. PubMed ID: 21854313 [TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. Liu J; Fu M; Wang M; Wan D; Wei Y; Wei X J Hematol Oncol; 2022 Mar; 15(1):28. PubMed ID: 35303904 [TBL] [Abstract][Full Text] [Related]
18. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
19. Developing recombinant and synthetic vaccines for the treatment of melanoma. Restifo NP; Rosenberg SA Curr Opin Oncol; 1999 Jan; 11(1):50-7. PubMed ID: 9914879 [TBL] [Abstract][Full Text] [Related]
20. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice. Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]